LJAC
BPMC

L.J. Altfest & Co’s Blueprint Medicines BPMC Stock Holding History

L.J. Altfest & Co’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,243
Closed -$205K – 289
2023
Q2 		$205K Buy
+3,243
New +$176K 0.03% 280

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

L.J. Altfest & Co's BPMC Position: Q3 2023 in Review

L.J. Altfest & Co sold out of Blueprint Medicines (BPMC) in Q3 2023, closing a stake of 3,243 shares — an estimated $205K sold.

L.J. Altfest & Co first reported a position in BPMC in Q2 2023 and held it in 1 quarter. The position peaked at $205K in Q2 2023. 220 funds tracked by Wall St. Rank hold BPMC as of Q3 2023.

  • L.J. Altfest & Co reported no remaining Blueprint Medicines position as of Q3 2023 after selling out during the quarter.
  • L.J. Altfest & Co sold 3,243 Blueprint Medicines shares in Q3 2023, an estimated $205K.
  • L.J. Altfest & Co first reported a position in Blueprint Medicines in Q2 2023 and held it in 1 quarter.
  • L.J. Altfest & Co's Blueprint Medicines position peaked at $205K in Q2 2023.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2023.

Based on L.J. Altfest & Co's 13F filing for Q3 2023, filed 26 Oct 2023.